NCT01025427View on ClinicalTrials.gov

HIV Persistence and Viral Reservoirs

PHASE4CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

November 30, 2012

Study Completion Date

October 31, 2013

Conditions

HIVHIV Infections

Interventions

DRUG

Raltegravir, tenofovir/emtricitabine

16 controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.

Trial Locations (1)

94110

San Francisco General Hospital, San Francisco

Sponsors

Collaborators (1)

Gilead Sciences

All Listed Sponsors

collaborator

California HIV/AIDS Research Program

OTHER

collaborator

Gilead Sciences

INDUSTRY

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

University of California, San Francisco

OTHER

NCT01025427 - HIV Persistence and Viral Reservoirs | Biotech Hunter | Biotech Hunter